Arimoclomol
| Clinical data | |
|---|---|
| Trade names | Miplyffa |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H20ClN3O3 |
| Molar mass | 313.78 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Arimoclomol, sold under the brand name Miplyffa, is a medication used for the treatment of Niemann–Pick disease type C. It is taken by mouth.
The most common side effects include upper respiratory tract infection, diarrhea, and decreased weight.
Arimoclomol was approved for medical use in the United States in September 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.